Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Investment Strategy: Modeling P.IV Litigation Timelines For equity analysts covering branded pharmaceutical companies or generic drug manufacturers, P.IV litigation timelines are directly material to earnings models
Its an appealing prospectespecially since these drugs are offered at a fraction of the price of their name-brand counterparts and are often shipped overnight after a prospective patient fills out a quick online questionnaire
The lower copay, a fraction of what the drugs can cost out of pocket, will no doubt increase accessibility to nearly 4 million beneficiaries who could be eligible for a prescription
In a sub-analysis in people with albuminuria at baseline, lixisenatide reduced UACR by 21% (in people with microalbuminuria) 39% (in people with macroalbuminuria)
